Saracatinib ( DrugBank: Saracatinib )

3 diseases

6. パーキンソン病

臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03661125 (ClinicalTrials.gov)	April 11, 2019	4/9/2018	SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis	A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.	Parkinson Disease Psychosis	Drug: Saracatinib;Drug: Placebo Oral Tablet	King's College London	AstraZeneca;King's College Hospital NHS Trust	Recruiting	40 Years	N/A	All	30	Early Phase 1	United Kingdom

臨床試験数 : 39 / 薬物数 : 46 - (DrugBank : 20) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 137

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02737202 (ClinicalTrials.gov)	April 2016	31/3/2016	Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis	Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis	Pulmonary Lymphangioleiomyomatosis	Drug: saracatinib	Baylor College of Medicine	University of Cincinnati;Brigham and Women's Hospital;Stanford University;Loyola University;University of South Florida;National Institutes of Health (NIH)	Terminated	18 Years	65 Years	Female	28	Phase 2	United States
2	NCT02116712 (ClinicalTrials.gov)	August 2014	15/4/2014	The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)	The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)	Pulmonary Lymphangioleiomyomatosis	Drug: Saracatinib	Tony Eissa	University of Texas;University of Cincinnati	Completed	18 Years	65 Years	Both	9	Phase 1	United States

臨床試験数 : 40 / 薬物数 : 36 - (DrugBank : 6) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 95

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04307953 (ClinicalTrials.gov)	August 5, 2020	11/3/2020	Saracatinib Trial TO Prevent FOP	Saracatinib Trial TO Prevent FOP	Fibrodysplasia Ossificans Progressiva	Drug: AZD0530 Difumarate;Drug: Matching placebo	VU University Medical Center	Royal National Orthopaedic Hospital NHS Trust;Klinikum Garmisch-Patenkirchen;University of Oxford;Brigham and Women's Hospital;AstraZeneca;Innovative Medicines Initiative	Recruiting	18 Years	65 Years	All	20	Phase 2	Germany;Netherlands;United Kingdom
2	EUCTR2019-003324-20-NL (EUCTR)	08/01/2020	16/10/2019	A clinical trial to judge the safety, tolerability and effects on abnormal bone formation of reseach medication AZD 0530 (sarcatinib) in patients with FOP	Saracatinib trial TO Prevent FOP - STOPFOP	Fibrodyplasia Ossificans Progressiva (FOP) MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Saracatinib Product Code: AZD0530 INN or Proposed INN: Saracatinib Other descriptive name: SARACATINIB DIFUMARATE	VU University Medical Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	Netherlands